Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Non-Current Assets (2016 - 2025)

ImmunityBio (IBRX) has disclosed Non-Current Assets for 12 consecutive years, with $189.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Assets changed N/A to $189.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $776.4 million, a N/A change, with the full-year FY2024 number at $198.3 million, down 5.71% from a year prior.
  • Non-Current Assets was $189.5 million for Q3 2025 at ImmunityBio, down from $193.9 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $221.8 million in Q4 2022 to a low of -$212.3 million in Q1 2022.
  • A 5-year average of $157.7 million and a median of $196.5 million in 2024 define the central range for Non-Current Assets.
  • Biggest YoY gain for Non-Current Assets was 64.81% in 2022; the steepest drop was 293.29% in 2022.
  • ImmunityBio's Non-Current Assets stood at $134.6 million in 2021, then skyrocketed by 64.81% to $221.8 million in 2022, then fell by 5.15% to $210.4 million in 2023, then decreased by 5.71% to $198.3 million in 2024, then fell by 4.47% to $189.5 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Non-Current Assets are $189.5 million (Q3 2025), $193.9 million (Q2 2025), and $194.6 million (Q1 2025).